Contrastingly, in patients with kidney cancer and melanoma, low ANLN expression was associated with clinical benefits derived from ICB therapy (PD-L1 or PD-1), and thus longer OS (Figure 8B). This evidence concerns the gene PDCD1 and melanoma.